Nektar PEG-Irinotecan Moves Into Phase II For Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
By applying Nektar’s PEGylation technology to Camptosar, the drug may demonstrate more powerful and tolerable anti-tumor activity.